Clinical Trials Logo

Hip Necrosis clinical trials

View clinical trials related to Hip Necrosis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05142462 Active, not recruiting - Hip Fractures Clinical Trials

Post Market Clinical Follow-up of EUROSCUP Fixe Acetabular Cup

Start date: October 27, 2021
Phase:
Study type: Observational

EUROSCUP Fixe is intended for use in primary and revision total hip replacement surgery. Hip replacement is intended to provide increased patient mobility and reduce pain by replacing the damages hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. As part of post market vigilance, EUROS will collect data on EUROSCUP Fixe performances and safety

NCT ID: NCT04995822 Active, not recruiting - Hip Fractures Clinical Trials

Post Market Clinical Follow-up of EUROSTEM Femoral Stem

Start date: May 21, 2021
Phase:
Study type: Observational

EUROSSTEM is intended for use in primary and revision total hip replacement surgery. Hip replacement is intended to provide increased patient mobility and reduce pain by replacing the damages hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. As part of post market vigilance, EUROS will collect data on EUROSTEM performances and safety

NCT ID: NCT04993638 Recruiting - Hip Fractures Clinical Trials

Post Market Clinical Follow-up of Dual-mobility Acetabular Cup EUROSCUP MOBILE

Start date: June 1, 2021
Phase:
Study type: Observational

EUROSCUP MOBILE is intended for use in primary and revision total hip replacement surgery. Hip replacement is intended to provide increased patient mobility and reduce pain by replacing the damages hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. As part of post market vigilance, EUROS will collect data on EUROSCUP MOBILE performances and safety

NCT ID: NCT04210440 Completed - Hip Injuries Clinical Trials

The Treatment of Initial Stage of Hip Osteonecrosis: the Core Decompression

NEC15
Start date: March 1, 2003
Phase: N/A
Study type: Interventional

This retrospective study evaluates 52 cases of avascular necrosis of femoral head (AVN) treated by core decompression, bone chips allograft, fibrin platelet rich-plasma (PRF) and concentrated autologous mesenchymal stromal cells (MSCs).

NCT ID: NCT03326804 Active, not recruiting - Hip Osteoarthritis Clinical Trials

H1 Hip Resurfacing Arthroplasty

H1HRA
Start date: September 26, 2017
Phase:
Study type: Observational

This is a prospective, non-randomized, consecutive series, multicentre, observational study to evaluate the clinical outcome of ceramic-on- ceramic hip resurfacing arthroplasty using the ceramic, non-porous, non-cemented H1 Hip Resurfacing Arthroplasty. It includes a safety study followed by an efficacy study. Patients will be followed up for 10-years postoperatively. The primary aim is to confirm the safety of the H1 hip resurfacing prosthesis by demonstrating non-inferiority of the H1 device in terms of survivorship. The secondary is to evaluate superiority of the ceramic-on-ceramic H1 hip resurfacing prosthesis compared to Metal-on-Metal (MoM) hip resurfacing in terms of absence of metal ion release.The primary end point is revision for any reason.

NCT ID: NCT02114489 Terminated - Hip Necrosis Clinical Trials

Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis

Start date: June 2014
Phase: Phase 3
Study type: Interventional

Aseptic osteonecrosis of the hip (AOH) concern 1 Swiss young adult to 1000 (30-40 years old). They are responsible to a severe joint destruction and in the majority of cases a joint replacement. To the hip, we can distinguish 4 stages of osteonecrosis according to Ficat: 1, 2, 3, 4. Stage 3 and 4 AOH management are unanimous surgical. But management of stage 1 and 2 are unclear. Bisphophonates are mainly used for bone and osteoporosis diseases. They decrease the bone turn over, and the risk of fracture. They also decrease the bone marrow oedema and the pain associated to this oedema. Ibandronate is a bisphosphonate with a rapid effect, a short half-life, easy to manage, and with few side effects. We designed a double-blind prospective randomized trial aiming to evaluate the efficacy of an infusion of ibandronate versus placebo on pain and AOH progression in patients with stage 1 and 2 AOH. Our hypothesis is that there will be a pain reduction >=20 mm on the VAS scale (SD 10mm) in the ibandronate group versus placebo, and a non radiological progression in the treated group.